港股收評:2024年首週三大指數齊挫 科技股弱勢拖累市場走低
1月5日,港股午後跌幅擴大,恒生科技指數一度大跌至2.3%,最終收跌1.71%,恒指、國指分別下跌0.66%及0.75%,2024年首週三大指數集體下跌,恒科指跌4.6%表現最弱,恒指跌3%。

盤面上, 大型科技股普跌拖累大市下行,阿里巴巴跌超3%,騰訊跌超2%,網易、快手跌超1%,百度、美團飄紅;醫保局約談上藥第一生化督促降價,醫藥股集體下挫,生物科技股方向領跌;紙業股、餐飲股、手遊股、軍工股、汽車股、半導體股等紛紛表現低迷。
另一方面,家電股、電信股逆勢走俏,三大運營商集體拉昇,中國移動升近3%續創階段新高,教育股、影視娛樂股、石油股部分表現活躍,三桶油均有升幅。

具體來看
科網股升跌不一,嗶哩嗶哩跌超4%,阿里巴巴跌超3%,騰訊跌超2%,快手跌約2%,小米跌近1%,美團、百度小幅收升。

教育股升幅居前,新東方升超2%,天立國際、中國春來等跟升。

內房股衝高回落,龍光集團升近2%,華潤置地升近1%,綠城中國、龍湖集團等跟小幅收升。

中信證券日前指出,預計2024年不動產市場結構變化不少:預計按揭貸款利率走低,居民購房負擔下降,限購限貸繼續放鬆,推動改善性需求釋放;預計核心城市房價逐漸走穩,但低線城市房價繼續承壓;預計2024年保交付工作總體取得積極進展,三大工程託底投資,政策對沖債權人順週期傾向,穩定房企籌資性現金流。
汽車股多數下行,小鵬汽車跌超4%,理想汽車跌近4%,蔚來跌超2%,長城汽車、廣汽集團等跟跌。

醫藥股集體走弱,百濟神州跌超9%,金斯瑞生物科技、康方生物跌近4%,藥明康德跌超3%,藥明生物跌超2%。

昨晚,國家醫保局微信公眾號發佈約談上藥第一生化藥業,承諾將注射用硫酸多黏菌素B掛網價格從每支270元人民幣,進一步降低至123元人民幣,並保證穩定供應。
石油股延續走強,中國海洋石油升近2%,中國石油股份升超1%,中國石油化工小幅跟升。

蘋果概念股普遍走低,丘鈦科技跌超3%,高偉電子、比亞迪電子跌超2%,舜宇光學等跟跌。

消息面上,美國投資機構Piper Sandler將蘋果評級從“增持”下調至“中性”,理由是擔心iPhone的庫存水平和銷量增長率見頂。由於宏觀環境趨弱,Piper Sandler分析師Harsh Kumar預測蘋果將面臨挑戰。他還強調了高利率對蘋果整體業績的影響。
個股層面
同程旅行收升446%,報14.98港元創逾一個月新高,總市值336.5億港元。
消息上,旅遊市場近期持續升温,出境遊、冰雪遊皆表現亮眼。中銀證券研報指出,2024年元旦假期出遊人次和收入較去年中秋國慶的恢復程度均有所提升,市場景氣度仍然較高,看好市場後續的理性繁榮。業內普遍認為,出入境旅遊的熱度會從元旦假期延續至春節假期。
今日,南下資金淨買入16.07億港元,其中港股通(滬)淨買入12.59億港元,港股通(深)淨買入3.47億港元。

展望後市,國元國際指出,基於對市場環境的判斷,該行認為近期是尋找結構性機會的較好時機,當前市場外部環境趨穩,對於投資者來説適合進行優質個股的篩選和投資。雖然上週市場出現反彈,但該行認為在當前大的環境下港股的長期回升依然需要政策的支持以及經濟基本面的強勢恢復。本週是元旦假期後首個交易周,由於前期的快速反彈,本週市場有短期震盪的可能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.